Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-30

Clinical Trial Update: Eye Tracking as a Biomarker of Cannabis Effects [Phase 2]

View source ↗

Summary

Phase 2 trial investigating eye tracking as a biomarker of cannabis effects; the study was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Cannabis Use, Pain, Acute | Phase 2 | Status: TERMINATED | Results posted: 2022-06-30